This is a preprint.
Multi-omics profiling of mouse polycystic kidney disease progression at a single cell resolution
- PMID: 38854144
- PMCID: PMC11160654
- DOI: 10.1101/2024.05.27.595830
Multi-omics profiling of mouse polycystic kidney disease progression at a single cell resolution
Update in
-
Multiomics profiling of mouse polycystic kidney disease progression at a single-cell resolution.Proc Natl Acad Sci U S A. 2024 Oct 22;121(43):e2410830121. doi: 10.1073/pnas.2410830121. Epub 2024 Oct 15. Proc Natl Acad Sci U S A. 2024. PMID: 39405347 Free PMC article.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and causes significant morbidity, ultimately leading to end-stage kidney disease. PKD pathogenesis is characterized by complex and dynamic alterations in multiple cell types during disease progression, hampering a deeper understanding of disease mechanism and the development of therapeutic approaches. Here, we generate a single nucleus multimodal atlas of an orthologous mouse PKD model at early, mid and late timepoints, consisting of 125,434 single-nucleus transcriptomic and epigenetic multiomes. We catalogue differentially expressed genes and activated epigenetic regions in each cell type during PKD progression, characterizing cell-type-specific responses to Pkd1 deletion. We describe heterogeneous, atypical collecting duct cells as well as proximal tubular cells that constitute cyst epithelia in PKD. The transcriptional regulation of the cyst lining cell marker GPRC5A is conserved between mouse and human PKD cystic epithelia, suggesting shared gene regulatory pathways. Our single nucleus multiomic analysis of mouse PKD provides a foundation to understand the earliest changes molecular deregulation in a mouse model of PKD at a single-cell resolution.
Conflict of interest statement
Competing Interest Statement: B.D.H. is a consultant for Janssen Research & Development, LLC, Pfizer and Chinook Therapeutics, holds equity in Chinook Therapeutics and grant funding from Chinook Therapeutics and Janssen Research & Development, LLC. O.M.W has received grants from AstraZeneca unrelated to the current work. The remaining authors declare no competing interests.
Figures
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources